GT Biopharma Q2 Loss Narrows, Cash Runway Through Q4; Two TriKE Trials Advancing
GTBP is trading near its 52-week low of $0.261 (13% above the low) on light trading volume (0.4× avg).
Summary
GT Biopharma reported Q2 2026 results with R&D expenses up to $1.1M from $0.4M a year ago, reflecting increased clinical activity. Cash of $5.1M at June 30 is expected to fund operations through Q4 2026. Both TriKE candidates are progressing: GTB-3650 has completed Cohort 4 and is enrolling Cohort 5, while GTB-5550 has completed Cohort 1 and is enrolling Cohort 2. The company also anticipates IND clearance for an additional TriKE asset in 2026. This follows the Nasdaq minimum bid price deficiency and the pending reverse stock split proposal; the stock trades at $0.295, well below the $1.00 requirement. Updates on both trials are expected in 2H 2026.
At the time of this announcement, GTBP was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.26 to $1.74. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.